Abstracts tagged "pain"

Abstract Number: 1900 • ACR Convergence 2020
The Clinical and the Functional Impact of Central Sensitization on Patients with Axial Spondyloarthritis
Feyza Nur Yücel¹ and Mehmet Tuncay Duruöz², ¹Marmara University School of Medicine PMR Department, Istanbul, Turkey, ²Marmara University School of Medicine, PMR Department, Rheumatology Division, Istanbul, Turkey
Background/Purpose: To evaluate the impact of central sensitization (CS) on axial spondyloarthritis (AxSpA) patients’ clinical and functional situation and quality of life.Methods: Subjects with axSpA…
Abstract Number: 0373 • ACR Convergence 2020
Medical Cannabis in Ankylosing Spondylitis Following Recreational Legalization: A Prospective Cross-sectional Study
Emmanouil Rampakakis¹, Yoram Shir², John Sampalis¹, Martin Cohen², Michael Starr², Winfried Häuser³ and Mary-Ann Fitzcharles², ¹JSS Medical Research, St-Laurent, QC, Canada, ²McGill university, montreal, Canada, ³Technische Universität München, Munich, Germany
Background/Purpose: Recreational legalization of cannabis has influenced the medical use by patients. When only legal medical access was available in Canada, 4.3% of all rheumatology…
Abstract Number: 0811 • ACR Convergence 2020
Long-term Opioid Use in Patients with Rheumatoid Arthritis Treated with Sarilumab
Janet Pope¹, Amy Praestgaard², Hubert van Hoogstraten³, Melitza Iglesias-Rodriguez², Serge Perrot⁴, Yvonne Lee⁵, Anthony Sebba⁶ and Ernest Choy⁷, ¹Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ²Sanofi, Cambridge, MA, ³Sanofi, Bridgewater, NJ, ⁴Paris Descartes University, Paris, Ile-de-France, France, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Arthritis Associates, Palm Harbor, Tampa, FL, ⁷CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Prescription opioids are routinely used in patients with RA. However, use of opioids should be minimized to prevent abuse and addiction. Chronic opioid use…
Abstract Number: 1224 • ACR Convergence 2020
Glucocorticoid Reduction in Different Profiles of Patients with Rheumatoid Arthritis and Treatment with Sarilumab
Esteban Rubio Romero¹, Alejandro Muñoz Jiménez², Rosalia Martinez Perez³ and Lara Mendez Diaz⁴, ¹VIRGEN DEL ROCIO UNIVERSITY HOSPITAL, SEVILLE, Spain, ²H. U. Virgen del Rocío (Sevilla), Sevilla, Spain, ³Virgen del Rocío University Hospital, seville, Spain, ⁴Virgen del Rocío Hospital, sevilla, Spain
Background/Purpose: Glucocorticoid reduction in different profiles of patients with rheumatoid arthritis and sarilumab treatment. Real clinical practice studies are tasked with providing clinically relevant data…
Abstract Number: 1642 • ACR Convergence 2020
Observed Efficacy with Subcutaneous Tanezumab Is Early and Maintained in Patients with Osteoarthritis: Results from a 56-Week Randomized NSAID-Controlled Study
Tuhina Neogi¹, David Hunter², Melvin Churchill³, Ivan Shirinsky⁴, Masanari Omata⁵, Alexander White⁶, Ali Guermazi¹, Robert Fountaine⁷, Glenn Pixton⁸, Lars Viktrup⁹, Mark Brown⁷, Christine West¹⁰ and Kenneth Verburg¹¹, ¹Boston University School of Medicine, Boston, MA, ²Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia, ⁵Ohimachi Orthopaedic Clinic, Tokyo, Japan, ⁶Progessive Medical Research, Port Orange, FL, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc., Morrisville, NC, ⁹Eli Lilly and Company, Indianapolis, IN, ¹⁰Pfizer Inc, Groton, CT, ¹¹Pfizer Inc, Groton
Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…
Abstract Number: 1901 • ACR Convergence 2020
Clinical Characteristics of Importance to Outcome in Patients with Axial Spondyloarthritis: A Prospective Cohort Study
Rikke Asmussen Andreasen¹, Xenofon Baraliakos², Lars Erik Kristensen³, Kenneth Egstrup⁴, Vibeke Strand⁵, Hans Christian Horn⁶, Jimmi Wied⁶, Berit Schiøttz-Christensen⁷, Claus Aalykke¹, Inger Marie Hansen¹, Torkell Juulsgaard Ellingsen⁸ and Robin Christensen⁹, ¹Odense University Hospital, Svendborg, Svendborg, Denmark, ²Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, ³The Parker Institute Copenhagen Denmark, Copenhagen, Denmark, Bispebjerg and Frederiksberg, Denmark, ⁴Odense University Hospital Svendborg, Svendborg, Denmark, ⁵Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁶Odense University Hospital, Odense, Denmark, ⁷Spine Centre of Southern Denmark. Hospital lillebaelt, Middelfart, Denmark, ⁸Rheumatology Research Unit, Dept of Rheumatology Odense University Hospital, Odense C, Denmark, ⁹Musculoskeletal Statistics Unit, The Parker Institute/Odense University Hospital, Copenhagen F, Denmark
Background/Purpose: Despite better control of inflammation, many patients with axial spondyloarthritis (axSpA) still report pain, although they could be in remission. This suggests that in…
Abstract Number: 060 • 2020 Pediatric Rheumatology Symposium
Parsing Apart the Pain Experience: Exploring Treatment-Related Pain in Juvenile Idiopathic Arthritis
Yvonne Brandelli¹, Christine Chambers ², Perri Tutelman ¹, Jennifer Stinson ³, Adam Huber ⁴ and Jennifer Wilson ⁵, ¹Dalhousie University, Halifax, Nova Scotia, Canada, ²Dalhousie University & IWK Health Centre, Halifax, Nova Scotia, Canada, ³University of Toronto & The Hospital for Sick Children, Toronto, Ontario, Canada, ⁴IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ⁵Cassie and Friends, Vancouver, British Columbia, Canada
Background/Purpose: Pain is one of the most frequently reported symptoms among children with Juvenile Idiopathic Arthritis (JIA), and in recent decades our understanding and assessment…
Abstract Number: 097 • 2020 Pediatric Rheumatology Symposium
A Pilot Randomized Controlled Trial of the iCanCope Pain Self-management Application for Adolescents with Juvenile Idiopathic Arthritis
Chitra Lalloo ¹, Lauren Harris ², Amos Hundert ², Roberta Berard ³, Joseph Cafazzo ⁴, Mark Connelly ⁵, Brian Feldman ², Kristin Houghton ⁶, Adam Huber ⁷, Ronald Laxer ⁸, Nadia Luca ⁹, Heinrike Schmeling ¹⁰, Lynn Spiegel ¹¹, Lori Tucker ¹², Quynh Pham ⁴, Cleo Davies-Chalmers ¹³ and Jennifer Stinson¹⁴, ¹The Hospital for Sick Children, Toronto, Ontario, Canada, ²The Hospital for Sick Children, Toronto, Canada, ³Children's Hospital London Health Sciences Centre, London, Canada, ⁴University of Toronto, Toronto, Canada, ⁵Kansas City, ⁶University of British Columbia - Vancouver, Vancouver, Canada, ⁷IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ⁸The Hospital for Sick Children and University of Toronto, Toronto, Canada, ⁹University of Calgary, Calgary, Alberta, Canada, ¹⁰Alberta Children's Hospital/University of Calgary, Calgary, Alberta, Canada, ¹¹University of Toronto/Hospital for Sick Children, Thornhill, Canada, ¹²BC Children's Hospital, Vancouver, British Columbia, Canada, ¹³The Hospital for Sick Children, Toonto, Canada, ¹⁴University of Toronto & The Hospital for Sick Children, Toronto, Ontario, Canada
Background/Purpose: Pain is the most common symptom of Juvenile Idiopathic Arthritis (JIA), a chronic childhood illness that has potentially debilitating effects on health-related quality of…
Abstract Number: 110 • 2020 Pediatric Rheumatology Symposium
Consequences and Predictors of Persisting Pain in Children with Juvenile Idiopathic Arthritis: A Case Control Study Nested in the ReACCh-Out Cohort
Tara McGrath¹, Jaime Guzman ², Lori Tucker ³, Natalie Shiff ⁴, Maryna Yaskina ⁵, Susan Tupper ⁶ and Dax Rumsey ⁷, ¹University of British Columbia, Vancouver, Canada, ²University of British Columbia and BC Children's Hospital, Vancouver, Canada, ³BC Children's Hospital, Vancouver, British Columbia, Canada, ⁴Florida, Gainesville, ⁵Women and Children's Research Institute, Edmonton, Canada, ⁶Saskatoon, Canada, ⁷University of Alberta, Edmonton, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease of childhood. Pain is a distressing and prevalent feature of JIA and can decrease…
Abstract Number: 115 • 2020 Pediatric Rheumatology Symposium
Carbohydrate and Sugar Intake Predict Pain in Teens with Active JIA Disease but Not in Teens in Remission or Controls: A Cross-Sectional, Case-Control Metabolomics Pilot Study
Kimberly Lewis¹, Nico Osier ², Patricia Carter ³, Christina Nguyen ⁴, Ruy Carrasco ⁵, Shelby Brooks ², Alexandra Garcia ⁶ and Stefano Tiziani ⁵, ¹The University of Texas at Austin, Austin, Texas, ²The University of Texas at Austin, Austin, ³University of Alabama, Tuscalossa, ⁴Ascension Seton Nursing Research, Austin, ⁵The University of Texas at Austin, Dell Medical School, Austin, ⁶The University of Texas at Austin, Dell Medical School, School of Nursing, Austin
Background/Purpose: The purpose of this study is to define the relationships between pain and carbohydrate metabolism in teens with active juvenile idiopathic arthritis (JIA), teens…
Abstract Number: L03 • 2019 ACR/ARP Annual Meeting
NYX-2925 Impacts Functional and Chemical Neuroimaging Biomarkers and Patient-reported Outcomes of Pain in Patients with Fibromyalgia
Steven Harte ¹, Leslie Arnold ², Eric Ichesco ¹, Christopher Crumb ¹, Mary Suh ³, Laurel Sindelar ³, Chelsea Kaplan ¹, Tony Larkin ¹, Andrew Schrepf ¹, Daniel Clauw ⁴, Stephen Sainati ³ and Richard Harris¹, ¹University of Michigan, Ann Arbor, ²University of Cincinnati College of Medicine, Cincinnati, ³Aptinyx Inc, Evanston, ⁴Division of Rheumatology, Department of Internal Medicine and Division of Anesthesia, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Fibromyalgia (FM) is a chronic, debilitating disease typified by widespread musculoskeletal pain and accompanied by fatigue, sleep disturbance, memory issues, and mood disorders. FM…
Abstract Number: 197 • 2019 ACR/ARP Annual Meeting
The Relationship Between Pain and Patient Demographics, Clinical Features, and Health Outcomes in a Cohort of Rheumatoid Arthritis Patients Recruited and Studied Using a Mobile Application
Harriet Dickinson ¹, Yunhao Liu ² and Rachel Williams³, ¹GSK, Stevenage, United Kingdom, ²GSK, Upper providence, ³GSK, Upper Providence, PA
Background/Purpose: Pain is one of the most pressing problems for Rheumatoid Arthritis (RA) patients and contributes substantially towards fatigue and disability. Experiences of pain in…
Abstract Number: 912 • 2019 ACR/ARP Annual Meeting
Co-morbidities Associated with Discordance Between Structural Severity and Pain in Osteoarthritis: Implications for Clinical Trial Design in OA – a Post-Hoc Analysis of Data from Two Randomized Controlled Trials
Jonathan Bjerre-Bastos¹, Inger Byrjalsen ², Morten Karsdal ³, Jeppe Andersen ¹ and Asger Bihlet ¹, ¹Nordic Bioscience Clinical Development, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Nordic Bioscience, Copenhagen, Denmark
Background/Purpose: Development of new disease-modifying drugs in osteoarthritis (DMOADs) has proven difficult and is complicated by heterogeneous study populations and insensitive endpoints of structural change,…
Abstract Number: 1216 • 2019 ACR/ARP Annual Meeting
Pilot, Randomized, Double-Blinded, Placebo Controlled Efficacy AndSafety Study of a Transdermal Alkalinizing and Pain Relieving Treatment ForAcute Gout Flare
Smitha Reddy¹, Ray Mabaquiao ² and Lisa Misell ³, ¹Arthritis Care and Research Inc., Poway, CA, ²Triwest Research, El Cajon, CA, ³Dyve Biosciences, San Diego, CA
Background/Purpose: Gout is characterized by a build-up of uric acid crystals in and around the joints. Uric acid crystal formation and dissolution is affected by…
Abstract Number: 1249 • 2019 ACR/ARP Annual Meeting
Pelvic Congestion Syndrome, an Uncommon Cause of Osteoarticular Pain
Mireia Castillo-Vilella¹, Jose Luis Tandaipan ², Laura Berbel ³, Lluís Moga ³, Georgina Salvador ³, Silvia Martínez-Pardo ³ and Nuria Giménez ³, ¹Hospital Universitari Sagrat Cor, Barcelona, Spain, ²Hospital Universitari Mutua Terrassa, Terrassa, Spain, ³Hospital Universitari Mútua Terrassa, Terrassa
Background/Purpose: Background: The pelvic congestion syndrome (PCS) is an under and often misdiagnosed entity that appears more frequently in premenopausal age and multiparous women. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].